{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:18:15Z","timestamp":1790205495662,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,12,10]],"date-time":"2014-12-10T00:00:00Z","timestamp":1418169600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s13318-014-0247-0","type":"journal-article","created":{"date-parts":[[2014,12,9]],"date-time":"2014-12-09T10:54:06Z","timestamp":1418122446000},"page":"149-155","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Frequencies of UGT1A4*2 (P24T) and *3 (L48V) and their effects on serum concentrations of lamotrigine"],"prefix":"10.1007","volume":"41","author":[{"given":"Arne","family":"Reimers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenche","family":"Sjursen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grethe","family":"Helde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eylert","family":"Brodtkorb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,10]]},"reference":[{"key":"247_CR1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/00498250902745082","volume":"39","author":"UA Argikar","year":"2009","unstructured":"Argikar UA, Remmel RP (2009) Variation in glucuronidation of lamotrigine in human liver microsomes. Xenobiotica Fate Foreign Compd Biol Syst 39:355\u2013363. doi: 10.1080\/00498250902745082","journal-title":"Xenobiotica Fate Foreign Compd Biol Syst"},{"key":"247_CR2","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/FPC.0b013e3283331637","volume":"19","author":"MO Benoit-Biancamano","year":"2009","unstructured":"Benoit-Biancamano MO, Adam JP, Bernard O, Court MH, Leblanc MH, Caron P, Guillemette C (2009) A pharmacogenetics study of the human glucuronosyltransferase UGT1A4. Pharmacogenet Genomics 19:945\u2013954. doi: 10.1097\/FPC.0b013e3283331637","journal-title":"Pharmacogenet Genomics"},{"key":"247_CR3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/FTD.0b013e3181ceecc6","volume":"32","author":"M Blanca Sanchez","year":"2010","unstructured":"Blanca Sanchez M et al (2010) UGT2B7_-161C>T polymorphism is associated with lamotrigine concentration-to-dose ratio in a multivariate study. Ther Drug Monit 32:177\u2013184. doi: 10.1097\/FTD.0b013e3181ceecc6","journal-title":"Ther Drug Monit"},{"key":"247_CR4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1528-1167.2012.03671.x","volume":"54","author":"MJ Brodie","year":"2013","unstructured":"Brodie MJ, Mintzer S, Pack AM, Gidal BE, Vecht CJ, Schmidt D (2013) Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia 54:11\u201327. doi: 10.1111\/j.1528-1167.2012.03671.x","journal-title":"Epilepsia"},{"key":"247_CR5","unstructured":"Chan HF (2013) Faktorer av betydning for variasjon i serumkonsentrasjonen av lamotrigin og lamotrigin 2-N-glukuronid. Master thesis, University of Oslo"},{"key":"247_CR6","author":"Y Chang","year":"2014","unstructured":"Chang Y, Yang LY, Zhang MC, Liu SY (2014) Correlation of the UGT1A4 gene polymorphism with serum concentration and therapeutic efficacy of lamotrigine in Han Chinese of Northern China. Eur J Clin Pharmacol. doi: 10.1007\/s00228-014-1690-1","journal-title":"Eur J Clin Pharmacol"},{"key":"247_CR7","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/clpt.1987.193","volume":"42","author":"AF Cohen","year":"1987","unstructured":"Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW (1987) Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 42:535\u2013541","journal-title":"Clin Pharmacol Ther"},{"key":"247_CR8","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1528-1167.2007.01414.x","volume":"49","author":"KL Davis","year":"2008","unstructured":"Davis KL, Candrilli SD, Edin HM (2008) Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Epilepsia 49:446\u2013454. doi: 10.1111\/j.1528-1167.2007.01414.x","journal-title":"Epilepsia"},{"key":"247_CR9","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1124\/dmd.112.048157","volume":"41","author":"VK Edavana","year":"2013","unstructured":"Edavana VK, Dhakal IB, Williams S, Penney R, Boysen G, Yao-Borengasser A, Kadlubar S (2013) Potential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomics. Drug Metab Dispos Biol Fate Chem 41:870\u2013877. doi: 10.1124\/dmd.112.048157","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"247_CR10","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/hep.20131","volume":"39","author":"U Ehmer","year":"2004","unstructured":"Ehmer U, Vogel A, Schutte JK, Krone B, Manns MP, Strassburg CP (2004) Variation of hepatic glucuronidation: novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. Hepatology 39:970\u2013977. doi: 10.1002\/hep.20131","journal-title":"Hepatology"},{"key":"247_CR11","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/FPC.0b013e328348c76b","volume":"21","author":"KK Erickson-Ridout","year":"2011","unstructured":"Erickson-Ridout KK, Zhu J, Lazarus P (2011) Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants. Pharmacogenet Genomics 21:539\u2013551. doi: 10.1097\/FPC.0b013e328348c76b","journal-title":"Pharmacogenet Genomics"},{"key":"247_CR12","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/FPC.0b013e328354026b","volume":"22","author":"KK Erickson-Ridout","year":"2012","unstructured":"Erickson-Ridout KK, Sun D, Lazarus P (2012) Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)(7)TAA and UGT1A4 L48V polymorphisms. Pharmacogenet Genomics 22:561\u2013576. doi: 10.1097\/FPC.0b013e328354026b","journal-title":"Pharmacogenet Genomics"},{"key":"247_CR13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.yebeh.2012.08.027","volume":"25","author":"E Faught","year":"2012","unstructured":"Faught E (2012) Adherence to antiepilepsy drug therapy. Epilepsy Behav 25:297\u2013302. doi: 10.1016\/j.yebeh.2012.08.027","journal-title":"Epilepsy Behav"},{"key":"247_CR14","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/epi.12318","volume":"54","author":"C Ghosh","year":"2013","unstructured":"Ghosh C, Hossain M, Puvenna V, Martinez-Gonzalez J, Alexopolous A, Janigro D, Marchi N (2013) Expression and functional relevance of UGT1A4 in a cohort of human drug-resistant epileptic brains. Epilepsia 54:1562\u20131570. doi: 10.1111\/epi.12318","journal-title":"Epilepsia"},{"key":"247_CR15","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00228-009-0783-8","volume":"66","author":"R Ghotbi","year":"2010","unstructured":"Ghotbi R, Mannheimer B, Aklillu E, Suda A, Bertilsson L, Eliasson E, Osby U (2010) Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure\u2014an impact similar to male gender or smoking in schizophrenic patients. Eur J Clin Pharmacol 66:465\u2013474. doi: 10.1007\/s00228-009-0783-8","journal-title":"Eur J Clin Pharmacol"},{"key":"247_CR16","author":"AK Greer","year":"2014","unstructured":"Greer AK et al (2014) A potential role for human UDP-glucuronosyltransferase (UGT) 1A4 promoter SNPs in the pharmacogenomics of tamoxifen and its derivatives. Drug Metab Dispos Biol Fate Chem. doi: 10.1124\/dmd.114.058016","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"247_CR17","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1528-1157.1999.tb00807.x","volume":"40","author":"AH Guberman","year":"1999","unstructured":"Guberman AH et al (1999) Lamotrigine-associated rash: risk\/benefit considerations in adults and children. Epilepsia 40:985\u2013991","journal-title":"Epilepsia"},{"key":"247_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2011.01.016","volume":"95","author":"MI Gulcebi","year":"2011","unstructured":"Gulcebi MI, Ozkaynakci A, Goren MZ, Aker RG, Ozkara C, Onat FY (2011) The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy. Epilepsy Res 95:1\u20138. doi: 10.1016\/j.eplepsyres.2011.01.016","journal-title":"Epilepsy Res"},{"key":"247_CR19","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/clpt.2012.46","volume":"92","author":"T Haslemo","year":"2012","unstructured":"Haslemo T et al (2012) UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in patients on maintenance treatment and in recombinant systems. Clin Pharmacol Ther 92:221\u2013227. doi: 10.1038\/clpt.2012.46","journal-title":"Clin Pharmacol Ther"},{"key":"247_CR20","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2125.1997.00594.x","volume":"43","author":"Z Hussein","year":"1997","unstructured":"Hussein Z, Posner J (1997) Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol 43:457\u2013465","journal-title":"Br J Clin Pharmacol"},{"key":"247_CR21","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/00003088-200645110-00002","volume":"45","author":"SI Johannessen","year":"2006","unstructured":"Johannessen SI, Tomson T (2006) Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet 45:1061\u20131075. doi: 10.2165\/00003088-200645110-00002","journal-title":"Clin Pharmacokinet"},{"key":"247_CR22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.pharmthera.2004.10.013","volume":"106","author":"TK Kiang","year":"2005","unstructured":"Kiang TK, Ensom MH, Chang TK (2005) UDP-glucuronosyltransferases and clinical drug\u2013drug interactions. Pharmacol Ther 106:97\u2013132","journal-title":"Pharmacol Ther"},{"key":"247_CR23","first-page":"31","volume":"10","author":"DW Kim","year":"2006","unstructured":"Kim DW, Kim M, Lee SK, Kang R, Lee SY (2006) Lack of association between L48V polymorphism in the UGT1A4 gene and lamotrigine-induced rash. J Korean Epilepsy Soc 10:31\u201334","journal-title":"J Korean Epilepsy Soc"},{"key":"247_CR24","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1124\/dmd.111.039040","volume":"39","author":"I Laverdiere","year":"2011","unstructured":"Laverdiere I, Caron P, Harvey M, Levesque E, Guillemette C (2011) In vitro investigation of human UDP-glucuronosyltransferase isoforms responsible for tacrolimus glucuronidation: predominant contribution of UGT1A4. Drug Metab Dispos Biol Fate Chem 39:1127\u20131130. doi: 10.1124\/dmd.111.039040","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"247_CR25","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/00004714-200110000-00008","volume":"21","author":"HL Liston","year":"2001","unstructured":"Liston HL, Markowitz JS, DeVane CL (2001) Drug glucuronidation in clinical psychopharmacology. J Clin Psychopharmacol 21:500\u2013515","journal-title":"J Clin Psychopharmacol"},{"key":"247_CR26","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1007\/s11033-012-2393-2","volume":"40","author":"M Lopez","year":"2013","unstructured":"Lopez M et al (2013) Interethnic differences in UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations. Mol Biol Rep 40:3187\u20133192. doi: 10.1007\/s11033-012-2393-2","journal-title":"Mol Biol Rep"},{"key":"247_CR27","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/01.fpc.0000173483.13689.56","volume":"15","author":"PI Mackenzie","year":"2005","unstructured":"Mackenzie PI et al (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677\u2013685","journal-title":"Pharmacogenet Genomics"},{"key":"247_CR28","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/humu.20946","volume":"30","author":"V Menard","year":"2009","unstructured":"Menard V, Girard H, Harvey M, Perusse L, Guillemette C (2009) Analysis of inherited genetic variations at the UGT1 locus in the French\u2013Canadian population. Hum Mutat 30:677\u2013687. doi: 10.1002\/humu.20946","journal-title":"Hum Mutat"},{"key":"247_CR29","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1124\/dmd.104.002576","volume":"33","author":"A Mori","year":"2005","unstructured":"Mori A, Maruo Y, Iwai M, Sato H, Takeuchi Y (2005) UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation. Drug Metab Dispos Biol Fate Chem 33:672\u2013675. doi: 10.1124\/dmd.104.002576","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"247_CR30","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.placenta.2004.09.006","volume":"26","author":"P Myllynen","year":"2005","unstructured":"Myllynen P, Pasanen M, Pelkonen O (2005) Human placenta: a human organ for developmental toxicology research and biomonitoring. Placenta 26:361\u2013371. doi: 10.1016\/j.placenta.2004.09.006","journal-title":"Placenta"},{"key":"247_CR31","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1124\/dmd.108.021428","volume":"36","author":"A Nakamura","year":"2008","unstructured":"Nakamura A, Nakajima M, Yamanaka H, Fujiwara R, Yokoi T (2008) Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos Biol Fate Chem 36:1461\u20131464. doi: 10.1124\/dmd.108.021428","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"247_CR32","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1528-1167.2007.01471.x","volume":"49","author":"I Ohman","year":"2008","unstructured":"Ohman I, Beck O, Vitols S, Tomson T (2008) Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy. Epilepsia 49:1075\u20131080. doi: 10.1111\/j.1528-1167.2007.01471.x","journal-title":"Epilepsia"},{"key":"247_CR33","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/01.jcp.0000169418.31275.a7","volume":"25","author":"A Reimers","year":"2005","unstructured":"Reimers A, Skogvoll E, Sund JK, Spigset O (2005) Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service. J Clin Psychopharmacol 25:342\u2013348","journal-title":"J Clin Psychopharmacol"},{"key":"247_CR34","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.eplepsyres.2011.02.002","volume":"94","author":"A Reimers","year":"2011","unstructured":"Reimers A, Helde G, Brathen G, Brodtkorb E (2011) Lamotrigine and its N2-glucuronide during pregnancy: the significance of renal clearance and estradiol. Epilepsy Res 94:198\u2013205. doi: 10.1016\/j.eplepsyres.2011.02.002","journal-title":"Epilepsy Res"},{"key":"247_CR35","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/dmd.106.009340","volume":"34","author":"A Rowland","year":"2006","unstructured":"Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, Miners JO (2006) In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine\u2013valproic acid interaction. Drug Metab Dispos Biol Fate Chem 34:1055\u20131062","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"247_CR36","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.biocel.2013.02.019","volume":"45","author":"A Rowland","year":"2013","unstructured":"Rowland A, Miners JO, Mackenzie PI (2013) The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol 45:1121\u20131132. doi: 10.1016\/j.biocel.2013.02.019","journal-title":"Int J Biochem Cell Biol"},{"key":"247_CR37","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2133\/dmpk.20.144","volume":"20","author":"M Saeki","year":"2005","unstructured":"Saeki M et al (2005) Genetic variations and haplotypes of UGT1A4 in a Japanese population. Drug Metab Pharmacokinet 20:144\u2013151","journal-title":"Drug Metab Pharmacokinet"},{"key":"247_CR38","doi-asserted-by":"crossref","first-page":"R50","DOI":"10.1186\/bcr1539","volume":"8","author":"D Sun","year":"2006","unstructured":"Sun D, Chen G, Dellinger RW, Duncan K, Fang JL, Lazarus P (2006) Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants. Breast Cancer Res BCR 8:R50. doi: 10.1186\/bcr1539","journal-title":"Breast Cancer Res BCR"},{"key":"247_CR39","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/humu.9432","volume":"27","author":"SS Thomas","year":"2006","unstructured":"Thomas SS, Li SS, Lampe JW, Potter JD, Bigler J (2006) Genetic variability, haplotypes, and htSNPs for exons 1 at the human UGT1A locus. Hum Mutat 27:717. doi: 10.1002\/humu.9432","journal-title":"Hum Mutat"},{"key":"247_CR40","unstructured":"UGT Alleles Nomenclature Home Page. UGT Nomenclature Committee. http:\/\/www.ugtalleles.ulaval.ca . Accessed 20 May 2014"},{"key":"247_CR41","first-page":"13","volume":"20","author":"FJ Vajda","year":"2013","unstructured":"Vajda FJ, Dodd S, Horgan D (2013) Lamotrigine in epilepsy, pregnancy and psychiatry\u2014a drug for all seasons? J Clin Neurosci Off J Neurosurg Soc Aust 20:13\u201316. doi: 10.1016\/j.jocn.2012.05.024","journal-title":"J Clin Neurosci Off J Neurosurg Soc Aust"},{"key":"247_CR42","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.2217\/pgs.11.105","volume":"12","author":"J Zhou","year":"2011","unstructured":"Zhou J, Argikar UA, Remmel RP (2011) Functional analysis of UGT1A4(P24T) and UGT1A4(L48V) variant enzymes. Pharmacogenomics 12:1671\u20131679. doi: 10.2217\/pgs.11.105","journal-title":"Pharmacogenomics"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-014-0247-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-014-0247-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-014-0247-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T03:11:06Z","timestamp":1650769866000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-014-0247-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,10]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["247"],"URL":"https:\/\/doi.org\/10.1007\/s13318-014-0247-0","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,10]]}}}